Stockscreener 앱 받기
4.92
3.98%
-0.19
Aldeyra Therapeutics Inc 주식(ALDX)의 최신 뉴스
Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Shares Bought by Barclays PLC - Defense World
Geode Capital Management LLC Has $6.01 Million Holdings in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
3 US Penny Stocks With Market Caps Over $80M To Watch - Simply Wall St
State Street Corp Purchases 16,188 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
Aldeyra Therapeutics (NASDAQ:ALDX) Stock Crosses Below 50 Day Moving AverageTime to Sell? - MarketBeat
Aldeyra, UnitedHealth Group Incorporated, Blue Ridge Bankshares, and Amplitude Investigation - The Bakersfield Californian
Aldeyra, UnitedHealth Group Incorporated, Blue Ridge - GlobeNewswire
Aldeyra Therapeutics: Key Inflection Point Ahead (NASDAQ:ALDX) - Seeking Alpha
4 Stock-ing Stuffers for Under $10 a Share - TheStreet
High Growth Tech Stocks To Watch In December 2024 - Simply Wall St
BNP Paribas Financial Markets Acquires 10,201 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Shares Sold by Verition Fund Management LLC - MarketBeat
Is the Options Market Predicting a Spike in Aldeyra Therapeutics (ALDX) Stock? - MSN
Aldeyra stock retains Outperform rating on strong DED drug outlook By Investing.com - Investing.com Australia
Aldeyra stock retains Outperform rating on strong DED drug outlook - Investing.com
Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Short Interest Down 12.3% in November - Defense World
Short Interest in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Drops By 12.3% - MarketBeat
Objective long/short (ALDX) Report - Stock Traders Daily
Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Shares Purchased by Jacobs Levy Equity Management Inc. - MarketBeat
Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Sees Large Increase in Short Interest - MarketBeat
Aldeyra Therapeutics CEO to Present at Citi Healthcare Conference Ophthalmology Panel - StockTitan
Final Deadline Alert: ALDX Investor Alert: Contact Bronstein, Ge - GuruFocus.com
Eagle Asset Management Inc. Lowers Stock Position in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - MarketBeat
ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap - MSN
Aldeyra announces FDA acceptance of resubmitted reproxalap application - MSN
Top US Penny Stocks To Watch In November 2024 - Simply Wall St
Perceptive Advisors buys 200,000 shares of Aldeyra Therapeutics Inc's common stock on Sept 19 - Reuters.com
Aldeyra Therapeutics (ALDX) Refiles NDA for Innovative Dry Eye Drug Reproxalap - GuruFocus.com
5,578 Shares in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Bought by US Bancorp DE - Defense World
BTIG sets shares target with buy rating on Aldeyra, cites FDA read - Investing.com
Aldeyra Therapeutics Shares Up, FDA to Review New Drug Application - MarketWatch
FDA reviews Aldeyra's dry eye disease drug candidate By Investing.com - Investing.com Canada
Aldeyra announces FDA acceptance of resubmitted reproxalap application (NASDAQ:ALDX) - Seeking Alpha
FDA reviews Aldeyra's dry eye disease drug candidate - Investing.com
Aldeyra's Dry Eye Drug Gets FDA Review, Expands $400M AbbVie Partnership Deal | ALDX Stock News - StockTitan
What is Leerink Partnrs' Forecast for ALDX FY2024 Earnings? - MarketBeat
Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Short Interest Update - MarketBeat
Research Analysts Issue Forecasts for ALDX FY2028 Earnings - MarketBeat
Aldeyra Therapeutics CEO to Present at Jefferies London Healthcare Conference | ALDX Stock News - StockTitan
Aldeyra Therapeutics Insiders Who Sold Avert US$58m Market Cap Dip - Simply Wall St
Aldeyra’s FDA Resubmission And AbbVie Option Revitalize Reproxalap’s Prospects (ALDX) - Seeking Alpha
Nephrotic Syndrome Drugs Market Analysis of the Competitive - openPR
Is BellRing Brands (BRBR) Outperforming Other Medical Stocks This Year? - Yahoo Finance
(ALDX) Trading Advice - Stock Traders Daily
4.33%
1.31%
자본화:
|
볼륨(24시간):